Filing Details

Accession Number:
0001213900-19-000521
Form Type:
13G Filing
Publication Date:
2019-01-10 12:11:39
Filed By:
Woodford Investment Management
Company:
Autolus Therapeutics Plc (NASDAQ:AUTL)
Filing Date:
2019-01-10
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Woodford Investment Management Ltd 0 298,935 0 11,925,419 11,925,419 29.7%
Neil Woodford 0 298,935 0 11,925,419 11,925,419 29.7%
Filing
 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

(Amendment No. 1)*

 

Autolus Therapeutics plc

(Name of Issuer)

 

American Depositary Shares and Ordinary Shares, nominal value $0.000042 per share

(Title of Class of Securities)

 

05280R 100**

(CUSIP Number)

 

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 05280R 100 has been assigned to the American Depositary Shares of the Company, which are quoted on the Nasdaq Global Select Market under the symbol “AUTL.” Each American Depositary Share represents 1 Ordinary Share.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

  

 

 

 

 

CUSIP NO. 05280R 100 SCHEDULE 13G Page 2 of 8

 

1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

 

Woodford Investment Management Ltd

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP    (a) ☒

                                                                                                                   (b) ☐ 

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United Kingdom

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING 
PERSON WITH
5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

298,935 Ordinary Shares, nominal value $0.000042 per share (“Ordinary Shares”) (see Item 4)

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER


11,925,419 Ordinary Shares (see Item 4)

 9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

11,925,419 Ordinary Shares (see Item 4)

 10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES        ☐

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

29.7% (See Item 4)

 12

TYPE OF REPORTING PERSON

 

FI

   

 

 

CUSIP NO. 05280R 100 SCHEDULE 13G Page 3 of 8

 

1

 

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

 

Neil Woodford

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP     (a) ☒

                                                                                                                  (b) ☐

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United Kingdom

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

298,935 Ordinary Shares (see Item 4)

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER


11,925,419 Ordinary Shares (see Item 4)

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

11,925,419 Ordinary Shares (see Item 4)

 10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES        ☐

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

29.7% (See Item 4)

12

TYPE OF REPORTING PERSON

 

IN

  

 

 

CUSIP NO. 05280R 100 SCHEDULE 13G Page 4 of 8

 

Item 1(a). Name of Issuer:
   
  Autolus Therapeutics plc (the “Issuer”).
   
Item 1(b). Address of Issuer’s Principal Executive Offices:
   
 

Forest House, 58 Wood Lane

White City

London W12 7RZ, United Kingdom

   
Items 2(a),  
(b) and (c). Name of Persons Filing, Address of Principal Business Office and Citizenship:
   
  This Schedule 13G is being filed jointly by Woodford Investment Management Ltd (the “Manager”) and Neil Woodford, the Head of Investment for the Manager. The joint filing agreement of the Manager and Mr. Woodford is attached as Exhibit 1 to this Schedule 13G. The filers of this statement are collectively referred to herein as the “Group.”
   
  The principal business office of the Manager and Mr. Woodford is 9400 Garsington Road, Oxford OX4 2HN, United Kingdom. For the place of organization of the Manager and the citizenship of Mr. Woodford, see Item 4 of their respective cover pages.    
   
Item 2(d). Title of Class of Securities:
   
  Ordinary Shares, nominal value $0.000042 per share (“Ordinary Shares”) represented by American Depositary Shares (“ADS”), each of which represents one Ordinary Share.
   
Item 2(e). CUSIP Number:
   
  There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 05280R 100 has been assigned to the ADS, which are quoted on the Nasdaq Global Select Market under the symbol “AUTL.”

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

  (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

  (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐ 78c).

 

  (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

 

  (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

  (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

  

 

  

CUSIP NO. 05280R 100 SCHEDULE 13G Page 5 of 8

  

  (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
       
  (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

  (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

  (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

 

  (k)

Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: The Manager is eligible to file pursuant to §240.13d-1(b)(1)(ii)(J) and is an investment manager authorized and regulated by the Financial Conduct Authority of the United Kingdom which is comparable to the regulatory scheme applicable to the investment advisers covered by Item 3(e) above. See Exhibit 1 for the identification and classification of each member of the Group.

 

Item 4. Ownership.(1)

 

 

 

(1) The Manager is the investment manager of LF Woodford Equity Income Fund, LF Woodford Income Focus Fund, Woodford Patient Capital Trust plc, Omnis Income & Growth Fund, Quilter Investors UK Equity Income II Fund (“Quilter”) (collectively, the “Shared Voting Funds”) and the West Fund (together, with the Shared Voting Funds, the “Woodford Funds”), providing services to (a) the Woodford Funds, (b) Link Fund Solutions, the operator of LF Woodford Equity Income Fund, LF Woodford Income Focus Fund and Woodford Patient Capital Trust plc, (c) Omnis Investments Limited, the operator of Omnis Income & Growth Fund and (d) the Abu Dhabi Investment Authority, the operator of the West Fund. Pursuant to the respective Management Agreements between each Woodford Fund and the Manager (collectively, the “Management Agreements”), the Manager (i) in the case of the Shared Voting Funds, has both voting power and investment discretion over securities held of record by each such fund, including, but subject to the proxy described in the following paragraph, any Ordinary Shares (represented by ADS) held of record by such fund and (ii) in the case of the West Fund, investment discretion (but not voting discretion) over securities held of record by the West Fund, including any Ordinary Shares (represented by ADS) held of record by the West Fund. Furthermore, the Management Agreement between the Manager and LF Woodford Equity Income Fund may be terminated by LF Woodford Equity Income Fund at any time upon 60 days’ notice. As a result, the Manager may be deemed to be the beneficial owner of the Ordinary Shares represented by ADS held by each Woodford Fund. Mr. Woodford is the Head of Investment for the Manager, and as such, may be deemed to beneficially own the Ordinary Shares (represented by ADS) beneficially owned by the Manager, but expressly disclaims such beneficial ownership except to the extent of any pecuniary interest therein. Of the Woodford Funds, as of the date hereof, each of LF Woodford Equity Income Fund and Woodford Patient Capital Trust plc beneficially own more than 5% of the issued and outstanding Ordinary Shares (represented by ADS) of the Issuer.

 

Four of the Woodford Funds (LF Woodford Equity Income Fund, LF Woodford Income Focus Fund, Omnis Income & Growth Fund and Woodford Patient Capital Trust plc (the “Autolus Funds”)), have executed irrevocable proxies (the “Manager Proxies”) appointing the Manager as the sole and exclusive attorney and proxy of each such fund to vote at any annual, special or adjourned meeting of the shareholders of the Issuer or any class thereof and exercise all voting and related rights (to the fullest extent that the Autolus Funds are entitled to do so) with respect to all of the shares of capital stock of the Issuer (including Ordinary Shares represented by ADS) (the “Shares”) beneficially owned by such fund (the “Proxy Shares”). The Manager has entered into a voting agreement with the Issuer, pursuant to which it has executed an irrevocable proxy to the Issuer (the “Autolus Proxy”) appointing any designee of the Issuer as the sole and exclusive attorney and proxy of the Manager to represent the Manager and to vote at every meeting of the shareholders of the Issuer or any class thereof (including any actions by written consent) and exercise all voting and related rights (to the fullest extent that the Manager is entitled to do so) with respect to all Proxy Shares, which when added to the Shares beneficially owned by the West Fund, Quilter and Arix Bioscience plc (“Arix”), are in excess of 9.99% of the then outstanding capital stock of the Issuer in the same proportion as the shares voted by all other stockholders (excluding the Manager and Quilter) voting on or consenting to such matters.

 

Accordingly, the Manager and Mr. Woodford share voting power with respect to 298,935 Ordinary Shares (represented by 298,935 ADS) consisting of (i) 131,431 Ordinary Shares (represented by 131,431 ADS), which represent the Proxy Shares below the 9.99% threshold, over which the Manager retains voting control pursuant to the Manager Proxies and (ii) 167,504 Ordinary Shares (represented by 167,504 ADS), held of record by Quilter, which are not subject to the Autolus Proxy, but with respect to which voting power is also shared with Quilter pursuant to the terms of the Management Agreement with such fund, in each case based on (x) 40,146,182 Ordinary Shares outstanding as of September 30, 2018 as reported in the Issuer’s Annual Report on Form 20-F, filed with the SEC on November 23, 2018, (y) 167,504 Shares owned by Quilter as of December 31, 2018 and (z) 3,161,533 Shares owned by Arix, as disclosed in the Issuer’s Schedule 13D filed by Arix on July 6, 2018. As noted above, Mr. Woodford expressly disclaims the beneficial ownership described in the immediately preceding sentence, except to the extent of any pecuniary interest therein.

 

 

 

CUSIP NO. 05280R 100 SCHEDULE 13G Page 6 of 8

 

  (a) Amount beneficially owned:

 

As of the date of this filing, each member of the Group may be deemed to have beneficial ownership of 11,925,419 Ordinary Shares (represented by 11,925,419 ADS). Mr. Woodford, who, as Head of Investments for the Manager, may be deemed to share beneficial ownership with the Manager of the Ordinary Shares beneficially owned by the Manager, expressly disclaims beneficial ownership of such Ordinary Shares, except to the extent of any pecuniary interest therein.

 

  (b) Percent of class:

 

Based on 40,146,182 Ordinary Shares outstanding as of September 30, 2018 as reported in the Issuer’s Annual Report on Form 20-F, filed with the SEC on November 23, 2018, each member of the Group beneficially owns approximately 29.7% of the issued and outstanding Ordinary Shares (represented by ADS) of the Issuer.

 

  (c) Number of shares to which each member of the Group has:

 

  (i) Sole power to vote or direct the vote: 0
     
  (ii) Shared power to vote or direct the vote: 298,935 Ordinary Shares (represented by 298,935 ADS)
     
  (iii) Sole power to dispose or to direct the disposition of: 0
     
  (iv) Shared power to dispose of or direct the disposition of: 11,925,419 Ordinary Shares (represented by 11,925,419 ADS)

 

Item 5. Ownership of Five Percent or Less of a Class.

 

Not applicable.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

The Manager is an investment manager and the funds managed by it have the right to receive and the power to direct the receipt of dividends or the profits from the sale of such securities. LF Woodford Equity Income Fund and Woodford Patient Capital Trust plc each beneficially owns more than 5% of the issued and outstanding Ordinary Shares (represented by ADS) of the Issuer (see footnote (1) to Item 4(c)).

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

See Exhibit 1.

 

Item 9. Notice of Dissolution of a Group.

 

Not applicable.

 

Item 10. Certification.

 

By signing below each member of the Group certifies that, to the best of his or its knowledge and belief, (i) the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect and (ii) the foreign regulatory scheme applicable to investment managers authorized and regulated by the Financial Conduct Authority of the United Kingdom is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). Each member of the Group also undertakes to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. 

 

 

 

CUSIP NO. 05280R 100 SCHEDULE 13G Page 7 of 8

 

SIGNATURE

 

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated: January 10, 2019

 

  WOODFORD INVESTMENT MANAGEMENT LTD
       
  By: /s/ Chris Martin
    Name:  Chris Martin
    Title: Head of Compliance and Authorized Signatory
       
  /s/ Neil Woodford
  Neil Woodford

  

This Schedule 13G is being jointly filed by the Group. The Manager is an investment manager, authorized and regulated by the Financial Conduct Authority of the United Kingdom, in the business of investment management. Mr. Woodford serves as the Head of Investment for the Manager. Mr. Woodford, as a controlling person of the Manager, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended, of the securities beneficially owned by the Manager. Securities reported on this Schedule 13G as being beneficially owned by the Group were purchased on behalf of clients of the Manager.

 

Pursuant to Rule 13d-4, Mr. Woodford declares that the filing of this Schedule 13G shall not be deemed an admission by him that he is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any securities covered by this Schedule 13G.

 

 

 

CUSIP NO. 05280R 100 SCHEDULE 13G Page 8 of 8

 

EXHIBIT 1

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares (represented by ADS, each of which represents one Ordinary Share) of the Issuer and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

  

Dated: January 10, 2019

 

  WOODFORD INVESTMENT MANAGEMENT LTD
       
  By: /s/ Chris Martin
    Name:  Chris Martin
    Title: Head of Compliance and Authorized Signatory
       
  /s/ Neil Woodford
  Neil Woodford

 

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

 

The Group filing this Schedule 13G is comprised of Woodford Investment Management Ltd and Neil Woodford, its Head of Investment.

 

Item 3 Classification:

 

Woodford Investment Management Ltd:  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

Neil Woodford: A control person in accordance with § 240.13d-1(b)(1)(ii)(G).